Atrial Fibrillation Feasibility Certoparin Trial - AFFECT

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Certoparin; Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

• persistent AF (electrical cardioversion is planned)

• written informed consent

Exclusion Criteria:

• acute clinical signs of venous thromboembolism

• current oral anticoagulation

• indication for medical cardioversion